Faeth Therapeutics (FTH) Stock Price, News & Analysis
Company Description
Faeth Therapeutics (NASDAQ: FTH) is classified in the biotechnology industry within the Pharmaceutical Preparations sector and carries a market capitalization of $657.4M, ranking #3,369 among all listed U.S. companies by market cap.
For FY2025, Faeth Therapeutics reported net income of -$21.1M and diluted earnings per share of $-16.72.
This page collects what Stock Titan holds for FTH, including price data, latest news, SEC filings, insider trading activity, financial highlights, upcoming events, and short interest trends.
Stock Performance
Faeth Therapeutics (FTH) stock last closed at $24.59. At a market capitalization of $657.4M, FTH is classified as a small-cap stock with approximately 25.8M shares outstanding.
FTH Rankings
Latest News
Faeth Therapeutics has 4 recent news articles, with the latest published 2 days ago. Of the recent coverage, 2 articles coincided with positive price movement and 0 with negative movement. Key topics include earnings. View all FTH news →
SEC Filings
Faeth Therapeutics has filed 5 recent SEC filings, including 2 Form 8-K, 1 Form 3, 1 Form 4, 1 Form 10-Q. The most recent filing was submitted on August 4, 2026. SEC filings provide transparency into a company's financial condition, material events, and regulatory compliance. View all FTH SEC filings →
Insider Radar
Insider buying activity at Faeth Therapeutics over the past 90 days may reflect management confidence in the company's direction. Institutional investors and analysts often monitor insider purchases as a potential bullish indicator for the stock.
Financial Highlights
operating income reached -$22.3M, and net income was -$21.1M. Diluted earnings per share stood at $-16.72. The company generated -$20.5M in operating cash flow. With a current ratio of 5.06, the balance sheet reflects a strong liquidity position.
Upcoming Events
PIK-201 topline results
Interim Phase 1b/2 readout
Options full vesting
Faeth Therapeutics has 3 upcoming scheduled events. The next event, "PIK-201 topline results", is scheduled for September 1, 2026 (in 25 days). Investors can track these dates to stay informed about potential catalysts that may affect the FTH stock price.
Short Interest History
Short interest in Faeth Therapeutics (FTH) currently stands at 890.3 thousand shares, up 14.1% from the previous reporting period, representing 3.6% of the float. Since June 2026, short interest has increased by 14.1%. This relatively low short interest suggests limited bearish sentiment.
Days to Cover History
Days to cover for Faeth Therapeutics (FTH) currently stands at 3.8 days, down 45.8% from the previous period. This days-to-cover ratio represents a balanced liquidity scenario for short positions. The days to cover has decreased 45.8% over the past year, suggesting improved liquidity for short covering. The ratio has shown significant volatility over the period, ranging from 3.8 to 7.0 days.
FTH Company Profile & Sector Positioning
Faeth Therapeutics (FTH) operates in the Biotechnology industry within the broader Pharmaceutical Preparations sector and is listed on the NASDAQ. In monthly performance, the stock ranks #3,710 among all tracked companies.